Finch Therapeutics Group is developing novel microbial therapies to serve patients with serious unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses innovative machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience, building upon the science of fecal transplantation. Finch uses this human-first discovery approach to identify strains that drive clinical outcomes, developing therapies that deliver these microbial communities to patients. Through a strategic merger with Crestovo in 2017, Finch established a leading position in addressing the C. difficile epidemic with Crestovo's lead Full-Spectrum Microbiota product, CP101, which is currently being evaluated among patients suffering from recurrent C. difficile infections.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/05/18 | $36,000,000 | Series B |
Avenir Growth Capital Morgan Noble Shumway Capital Willett Advisors | undisclosed |
| 08/23/19 | $53,000,000 | Series C |
Avenir Growth Capital Morgan Noble OCV Partners Shumway Capital Susquehanna International Group Symbiosis Trans-Pacific Partners Willett Advisors | undisclosed |
| 09/17/20 | $90,000,000 | Series D |
Avenir Growth Capital Baupost Group DFO Management Humboldt Fund MSD Partners Octave Life Sciences OCV Partners OMX Ventures Shumway Capital SIG Symbiosis TPTF | undisclosed |
